

non-steroidal anti-inflammatory drug celecoxib, which is recited in new Claim 23 (see above). Claims that read on the elected species are Claims 7, 10 and new Claim 23.

It is understood that even if no claim designated as generic is found to be allowable, any restriction that may result from the above election of species is not applicable to Claims 1-6 or Claims 11-13, as these claims are not generic and do not depend from a generic claim.

Before he conducts his search, the examiner is asked to consider the following remarks. Generic Claims 7-10 all depend directly or indirectly from Claim 1, which pertains to treating psoriatic arthritis with TNFR:Fc. Thus, in searching the prior art to determine the patentability of Claim 1, it seems likely that the examiner will encounter all of the prior art that would be relevant to the various combinations described in Claims 7-10 and 23. Accordingly, the Applicant suggests that it would not impose any additional burden on the examiner if during his initial search he were to investigate all of the claimed species for their patentability vis-à-vis the prior art.


Amendments to the Claims:

Pursuant to the Applicant's response to the restriction requirement, Claims 1-13 are presently under consideration in the application. New Claim 23 has been added to the specification. Support for Claim 23 is found throughout the specification, for example at page 9, lines 12-29. Accordingly, this new claim does not constitute the addition of new matter.

CONCLUSION

If the examiner has any further questions or concerns he is asked to call the undersigned at her direct dial number given below.

Respectfully submitted,



Diana K. Sheiness, Ph.D.
Reg. No. 35,356
(206) 470-4818

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430